Genzyme Seeks Toss Of Investors' Insider Trading Suit
Genzyme Corp. has asked a federal judge to dismiss a shareholder suit that accuses company executives of misleading the U.S. Food and Drug Administration and selling $117 million worth of stock...To view the full article, register now.
Already a subscriber? Click here to view full article